Medicosnext
Roche: With a turnover of $53 billion, Swiss company Roche is the biggest pharmaceutical company in the world. The company is at the forefront of oncology, immunology, 
neuroscience, ophthalmology, and infectious diseases. Its biggest products are Ocrevus (for multiple sclerosis), Hemlibra (for haemophilia A), Tecentriq (for urothelial carcinoma, hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, and small cell lung cancer), and Perjeta (used in combination with trastuzumab and docetaxel for treatment of metastatic HER2-positive breast cancer and as a neoadjuvant in early HER2-positive breast cancer).
Pfizer: With a turnover of $49.7 billion, New York-based Pfizer specializes in cardiology, neurology, immunology, and oncology. Its biggest drugs are Irbrance (for HR-positive and 
HER2-negative breast cancer), Eliquis (for treatment and prevention of blood clots and to prevent stroke in people with nonvalvular atrial fibrillation), Lyrica (for diabetic peripheral neuropathy, epilepsy, fibromyalgia, neuralgia, neuropathic pain, and post herpetic neuralgia), and Xeljanz (for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis).
Johnson & Johnson: New Jersey-based Johnson & Johnson, with a turnover of $42.2 billion, is at third place. The company specializes in pharmaceuticals, medical devices,and consumer health goods. Its biggest products are Stelara (for psoriasis), Darzalex (for multiple myeloma), and Im bruvica (for B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia).
Novartis: Swiss company Novartis is at fifth place with $37.7 billion in sales. The company focuses on innovative medicines as well as generics and biosimilars. Its key products are Cosentyx (for treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis), Entresto (fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan for heart failure), and Zolgensma (gene therapy medication for spinal muscular atrophy).
Takeda: The largest pharmaceutical company in Asia, Japanese multinational Takeda had a turnover of $31.1 billion in 2019. The company focuses on oncology, rare diseases,neuroscience, and gastroenterology. Its biggest products are Entyvio (for ulcerative colitis and Crohn’s disease) and Velcade (for multiple myeloma and mantle cell lymphoma).
Merck: Another New Jersey-based company, Merck, takes fourth spot with sales of $41.8 billion. The company focuses on pharmaceuticals, vaccines, and animal health. Its biggest products are Keytruda (for melanoma, lung cancer, head and neck cancer, stomach cancer, and Hodgkin lymphoma), Gardasil (vaccine for prevention of certain strains of human papillomavirus), and Varivax (for active immunization for the prevention of varicella in individuals 12 months of age or older).
AbbVie: Created in 2013 as an offshoot of Abbott, Chicago-based AbbVie had a turnover of $33.4 billion in 2019. The company specializes in immunology, oncology, and neuroscience. Its key products are Humira (for arthritis, psoriasis, and Crohn’s disease), Imbruvica (for treatment of B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia), and Viekira (fixed-dose combination of ombitasvir, paritaprevir, and ritonavir for treatment of hepatitis C).
Bristol-Myers Squibb: This New York based company specializing in oncology, haematology, immunology, and cardiovascular disease had a turnover of $26.1 billion in 2019. Its biggest products are Eliquis ((for treatment and prevention of blood clots and to prevent stroke in people with nonvalvular atrial fibrillation), Opdivo (for melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, colon cancer, and liver cancer), and Orencia (for moderate to severe adult rheumatoid arthritis, juvenile idiopathic arthritis, and adult psoriatic arthritis)
Sanofi: French multinational Sanofi, with a turnover of $26.7 billion, focuses on specialty care, vaccines, and general medicines. Its key products are Plavix (antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk), Lantus (long-acting insulin used in the management of type I and type II diabetes.), Aubagio (for treatment of relapsing forms of multiple sclerosis), and Lovenox (anticoagulant medication for treatment and prevention of deep vein thrombosis and pulmonary embolism).
Amgen: California-based bio-technology multinational Amgen had sales of $23.4 billion 2019. The company focuses on cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. Its biggest drugs are Enbrel (for moderate to severe rheumatoid arthritis, moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, and ankylosing spondylitis), Neulasta (a man-made form of a protein that stimulates the growth of white blood cells, used to decrease the incidence of infection by treating neutropenia), Prolia (for the treatment of osteoporosis in women after menopause who are at high risk for fracture ), and XGEVA (for prevention of fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors).
(Note: Sales are only for pharmaceutical segment of the companies listed above)
Ref: Proclinical.com,
